Conversations Unplugged
with Dave Asprey
Join STEMREGEN Founder and Chief Science Officer, Christian Drapeau, in a fascinating discussion with Dave Asprey, the entrepreneur and author who coined the term biohacking. Recorded at the Biohacking Conference in Dallas, this episode of "Conversations Unplugged" explores what it takes to upgrade a human being — from lowering the cost of access to health tools, to the neurofeedback program behind 40 Years of Zen and its link to neuroplasticity.
Dave Asprey
Recorded at the Biohacking Conference in Dallas, this episode opens with Christian Drapeau thanking Dave Asprey for the term that gave a movement its name. Asprey recalls starting with a blog he assumed five people would read, after weighing 300 pounds and having what he describes as all the diseases of aging before he turned 30. Getting to the bottom of his own health, he says, turned the project from recovery into upgrading.
He traces the conference from its first edition twelve years earlier — a hundred people in a bar — to the 3,200 attendees in Dallas. Asprey describes his role as curation across the full cost spectrum: the things billionaires do and the things that are free, always looking for what lowers the cost of access. That, he explains, is where a product releasing millions of a person's own stem cells daily fits.
Asked what sustains him, Asprey says an idea alone is not motivation. The mission across his companies is to upgrade humanity — anything that makes people more conscious, more capable and better able to act as they intend. He argues people are wired to be kind to one another but only manage it when they are not afraid, hungry or alone.
The conversation closes on 40 Years of Zen, his five-day neurofeedback program in Seattle that he says around 1,500 CEOs, athletes and entrepreneurs have completed. He argues the key is measurement, because believing you have forgiven something while it still lingers makes it invisible. Drapeau connects the program's results to neuroplasticity and therefore to stem cells, and Asprey confirms STEMREGEN has been added to the protocol.